Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Insight Molecular Diagnostics (IMDX) FCF Margin (2020 - 2025)

Historic FCF Margin for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q3 2025 value amounting to 2135.38%.

  • Insight Molecular Diagnostics' FCF Margin rose 27489600.0% to 2135.38% in Q3 2025 from the same period last year, while for Sep 2025 it was 543.71%, marking a year-over-year increase of 23234300.0%. This contributed to the annual value of 1128.6% for FY2024, which is 4419900.0% up from last year.
  • Per Insight Molecular Diagnostics' latest filing, its FCF Margin stood at 2135.38% for Q3 2025, which was up 27489600.0% from 1279.54% recorded in Q2 2025.
  • Insight Molecular Diagnostics' 5-year FCF Margin high stood at 208.02% for Q4 2021, and its period low was 18291.04% during Q3 2022.
  • In the last 5 years, Insight Molecular Diagnostics' FCF Margin had a median value of 1475.59% in 2023 and averaged 2878.9%.
  • In the last 5 years, Insight Molecular Diagnostics' FCF Margin soared by 422625900bps in 2021 and then tumbled by -171382000bps in 2022.
  • Quarter analysis of 5 years shows Insight Molecular Diagnostics' FCF Margin stood at 208.02% in 2021, then crashed by -1733bps to 3813.87% in 2022, then skyrocketed by 61bps to 1492.99% in 2023, then soared by 75bps to 376.11% in 2024, then plummeted by -468bps to 2135.38% in 2025.
  • Its last three reported values are 2135.38% in Q3 2025, 1279.54% for Q2 2025, and 288.35% during Q1 2025.